Arcturus Therapeutics has entered into a strategic collaboration with Thermo Fisher Scientific to support the development of its cystic fibrosis drug candidate ARCT-032. Under the agreements, Thermo Fisher will provide up to $40 million in clinical manufacturing services, while Arcturus will commit up to $40 million for contract research services through a Thermo Fisher affiliate. If the drug is approved, Thermo Fisher would become the exclusive commercial manufacturer for a specified period.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding ARCTURUS THERAPEUTICS HOLDIN (ARCT)?

Major stakeholders currently include Federated Hermes, INC. ($25.5M), ARK Investment Management LLC ($21.4M), BlackRock, Inc. ($20.2M). Based on the latest 13F filings, there are a total of 125 tracked investment funds and institutions maintaining positions in ARCT.

What is the overall institutional sentiment toward ARCT recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $40.4M, driven by 70 managers accumulating shares while 62 reduced their exposure.

Which institutions have been selling or reducing their ARCT positions?

In the latest period, 38 funds trimmed their holdings, and 24 managers completely exited their positions. The aggregate reported sell value was $54.1M.

Are there any notable investors adding ARCT to their portfolios?

Yes, buying activity remains notable. 23 institutions opened new positions in {ticker}, and 47 existing holders added to their shares. The total reported buy value for the quarter amounted to $102.7M.